As interest rates fall, business development companies', or BDCs, return on equity will likely be pressured. Oppenheimer ...

Christopher Nolan’s Oppenheimer was that rare movie that was both a box office hit and a serious award winner. It also had ...

Oppenheimer said on Wednesday it no longer expects growth in U.S. investment banking revenue this year and slashed its ...

Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $10 from $18 and keeps an Outperform rating on the shares ...

Oppenheimer maintained its Outperform rating on AppLovin (NASDAQ:APP) while highlighting key points for the company from the ...

Oppenheimer analyst Steven Lichtman maintained a Buy rating on Alcon (ALC – Research Report) today and set a price target of $105.00. The ...

A popular theory frequently utilized by technical analysts suggests U.S. stocks could be headed for one last leg higher over ...

Oppenheimer called the expected M&A rebound under the Trump administration “delayed or cancelled” and downgraded to "perform" ...

(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

Oppenheimer initiated coverage on shares of Ouster (NYSE:OUST – Free Report) in a research note released on Thursday, MarketBeat reports. The brokerage issued an outperform rating and a $16.00 price ...

Oppenheimer upgraded The Mosaic Company (NYSE:MOS) to Outperform from Perform and set a price target of $33 given the fertilizer maker’s efforts to reduce costs, optimize its product portfolio, and ...

Oppenheimer maintained its Outperform rating on AppLovin (NASDAQ:APP) while highlighting key points for the company from the annual retail and e-commerce industry conference, Shoptalk 2025.